10.1097/00005072-199806000-00010
10.1080/15622970510029786
10.1016/S1474-4422(07)70178-3
10.1016/0022-510X(94)90298-4
10.1016/S0009-8981(01)00573-3
Reiber H, 2006, Neurlogische Labordiagnostik
10.1016/S0022-510X(00)00501-3
Cleveland DW, 1979, Conservation of microtubule associated proteins. Isolation and characterization of tau and the high molecular weight microtubule associated protein from chicken brain and from mouse fibroblasts and comparison to the corresponding mammalian brain proteins, JBiol Chem, 254, 12670, 10.1016/S0021-9258(19)86366-4
10.1016/0304-3940(86)90288-0
10.1016/S0021-9258(17)38495-8
10.1146/annurev.neuro.24.1.1121
10.1016/S0165-0173(00)00019-9
10.1016/S0896-6273(00)81106-X
10.1016/S0304-3940(98)00923-9
10.1007/s00415-003-1059-3
10.1016/S0304-3940(00)01697-9
10.1016/j.neurobiolaging.2006.03.010
10.1016/S0022-510X(00)00480-9
10.1016/S0361-9230(03)00087-X
10.1001/archneur.59.8.1267
10.1016/S0304-3940(02)00047-2
10.1016/S0006-8993(99)01848-X
10.1212/01.WNL.0000065889.42856.F2
10.1016/j.biopsych.2008.02.016
Glenner GG, 1984, The amyloid deposits in Alzheimer's disease: their nature and pathogenesis, Appl Pathol, 2, 357
10.1016/j.neuroscience.2006.08.027
10.1007/978-3-7091-6846-2_11
10.1523/JNEUROSCI.17-24-09407.1997
10.1212/01.WNL.0000046581.81650.D0
10.1016/j.neulet.2006.09.044
10.1046/j.1471-4159.2002.00818.x
10.1016/j.jns.2005.05.015
10.1007/s00702-007-0629-4
10.1016/S0140-6736(05)79256-4
10.1126/science.276.5321.2045
10.1016/S0140-6736(04)17103-1
10.1146/annurev.biochem.74.082803.133400
10.1523/JNEUROSCI.0692-05.2005
10.1016/j.jneumeth.2007.09.021
10.1080/00365510601161497
10.1016/j.bbrc.2006.08.024
10.1016/j.expneurol.2008.06.004
10.1016/S0304-3940(00)01153-8
10.1016/j.neulet.2008.11.015
10.1097/01.jnen.0000190063.90440.69
10.1097/01.wnr.0000224773.66904.e7
10.1002/1097-0029(20010101)52:1<65::AID-JEMT9>3.0.CO;2-4
10.1007/s00702-005-0427-9
10.1016/j.expneurol.2006.12.006
10.1016/S0021-9258(18)47992-6
10.1016/j.cccn.2004.09.001
10.1016/j.neulet.2004.07.061
10.1016/j.jns.2007.08.018
10.1016/0968-0004(88)90218-6
10.1007/s12028-007-0008-x
10.1111/j.1471-4159.1984.tb12739.x
10.1016/S0304-3940(02)00968-0
10.1016/j.neulet.2003.09.018
10.1016/j.parkreldis.2007.02.002
10.1016/j.tips.2006.05.006
10.1016/S0092-8674(00)81973-X
10.1016/S0896-6273(00)00058-1
10.1001/archneur.59.10.1553
Jellinger KA, 2001, The pathology of Parkinson's disease, Adv Neurol, 86, 55
10.1016/j.jns.2006.08.004
10.1016/j.parkreldis.2007.08.012
10.1016/j.neuron.2005.01.032
10.1007/s00018-004-4268-8
10.1016/S1353-8020(00)00083-3
Chesselet MF, 1983, Somatostatin regulates dopamine release in rat striatal slices and cat caudate nuclei, J Neurosci, 3, 232, 10.1523/JNEUROSCI.03-01-00232.1983
10.1007/s00415-002-0753-x
10.1016/S0021-9258(18)53593-6
10.1007/s00415-007-0610-z
10.1212/01.wnl.0000303973.71803.81
10.1097/WNN.0b013e31817995e7
10.1111/j.1600-0404.1996.tb00175.x
10.1016/S0304-3940(02)01259-4
10.1016/0006-8993(85)91032-7
10.1016/0006-3223(86)90328-8
10.1016/j.nbd.2006.11.011
10.1016/0006-8993(86)91401-0
10.1016/0022-510X(87)90102-X
Yoshinaga J, 1989, Acetylcholinesterase activity in CSF in senile dementia of Alzheimer type, vascular dementia, and Parkinson's disease, Rinsho Shinkeigaku, 29, 376
10.1016/0009-8981(95)06004-9
Polinsky RJ, 1988, Low lumbar CSF levels of homovanillic acid and 5‐hydroxyindoleacetic acid in multiple system atrophy with autonomic failure, J Neurol Neurosurg Psychiatry, 51, 914, 10.1136/jnnp.51.7.914
Konagaya M, 1992, [CSF acetylcholinesterase activity in central neurological diseases involving cholinergic systems], Rinsho Shinkeigaku, 32, 266
10.1001/archneur.1982.00510190009002
10.1111/j.1471-4159.1983.tb09051.x
de Jong PJ, 1984, CSF GABA levels in Parkinson's disease, Adv Neurol, 40, 427
10.1016/0006-8993(84)90475-X
10.1111/j.1600-0404.1986.tb03249.x
10.1016/0022-510X(96)00115-3
10.1016/S0022-510X(97)00119-6
10.1016/S0022-510X(97)00069-5
10.1016/0304-3940(91)90796-V
10.1016/S0022-510X(99)00167-7
10.1016/S0304-3940(02)01026-1
10.1007/s00702-004-0202-3
10.1111/j.1600-0404.1992.tb06042.x
10.1002/1531-8257(199911)14:6<1008::AID-MDS1015>3.0.CO;2-E
10.1016/0304-3940(96)12961-X
10.1016/j.parkreldis.2008.01.010
Chase TN, 1976, Biochemical aids in the diagnosis of Parkinson's disease, Ann Clin Lab Sci, 6, 4
Extein I, 1976, 14C‐homovanillic acid in the cerebrospinal fluid of parkinsonian patients after intravenous 14C‐L‐dopa, Biol Psychiatry, 11, 227
10.1001/archneur.1984.04050200041016
10.1001/archneur.1985.04060020037011
10.1001/archneur.1985.04060050091016
Kurlan R, 1988, Cerebrospinal fluid homovanillic acid and parkinsonism in Huntington's disease, Ann Neurol, 24, 282, 10.1002/ana.410240221
10.1016/0022-510X(89)90175-5
Fukuda H, 1989, [Study on the concentration of 5‐hydroxyindoleacetic acid (5‐HIAA) in the lumbar cerebrospinal fluid (CSF) in neurological diseases], Rinsho Shinkeigaku, 29, 1192
10.1016/0022-510X(93)90316-Q
Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease, 1995, Parkinson Study Group, Arch Neurol, 52, 237
10.1111/j.1600-0404.1995.tb01023.x
10.1016/0022-510X(95)00146-S
Gonzalez‐Quevedo A, 1993, Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system, Bol Estud Med Biol, 41, 13
Kanemaru K, 1998, Cerebrospinal fluid homovanillic acid levels are not reduced in early corticobasal degeneration, Neurosci Lett, 245, 121, 10.1016/S0304-3940(98)00181-5
10.1016/0022-510X(95)00110-N
Krygowska‐Wajs A, 1997, Salsolinol, 3‐O‐methyl‐dopa and homovanillic acid in the cerebrospinal fluid of Parkinson patients, Neurol Neurochir Pol, 31, 875
Botez MI, 2001, Biogenic amine metabolites and thiamine in cerebrospinal fluid in heredo‐degenerative ataxias, Can J Neurol Sci, 28, 134, 10.1017/S0317167100052811
10.1111/j.1748-1716.1986.tb07976.x
10.1111/j.1600-0404.1994.tb01631.x
10.1016/S0022-510X(97)00267-0
Cramer H, 1984, Analysis of neurotransmitter metabolites and adenosine 3',5'‐monophosphate in the CSF of patients with extrapyramidal motor disorders, Adv Neurol, 40, 431
10.1016/S0022-510X(96)00259-6
10.1097/00002093-199408030-00005
10.1016/j.jocn.2005.12.023
10.1016/j.bbrc.2006.05.011
10.1016/0885-4505(87)90049-1
10.1016/S0304-3940(99)00221-9
10.1111/j.1471-4159.1990.tb08814.x
10.1111/j.1468-1331.2006.01139.x
10.1016/j.lfs.2005.02.014
10.1016/0304-3940(95)12192-7
10.1111/j.1600-0404.1998.tb01736.x
10.1001/archneur.60.9.1218
10.1016/j.chemphyslip.2003.10.010
10.1016/j.jtemb.2007.05.001
10.1007/978-3-211-33328-0_24
10.1007/s00702-004-0124-0
Jimenez‐Jimenez FJ, 1998, Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease, J Neural Transm, 105, 497, 10.1007/s007020050073
Ilic T, 1998, Oxidative stress and Parkinson's disease, Vojnosanit Pregl, 55, 463
10.1111/j.1600-0404.1967.tb05735.x
Bostrom F, 2008, CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies, Neurobiol Aging
10.1016/0024-3205(92)90549-5
10.1016/0885-4505(90)90049-7
Yamada T, 1993, Concentration of neural thread protein in cerebrospinal fluid from progressive supranuclear palsy and Parkinson's disease, Jpn J Psychiatry Neurol, 47, 631
10.1046/j.1471-4159.1996.67052013.x
10.1016/0143-4179(91)90138-9
10.1136/jnnp.53.12.1105-a
10.1016/0022-510X(87)90118-3
10.1111/j.1600-0404.1992.tb05067.x
10.1097/00001756-199508000-00013
10.1080/00207450500513989
10.1111/j.1600-0404.1996.tb00186.x
10.1007/s00415-004-0311-9
10.1007/s00702-004-0235-7
10.1097/00002093-199803000-00004
10.1002/1531-8249(200004)47:4<524::AID-ANA19>3.0.CO;2-5
10.1016/j.neurobiolaging.2007.05.009
10.1007/s00702-003-0075-x
10.1007/s00702-006-0537-z
10.1016/j.neuint.2005.11.002
Urakami K, 2002, Corticobasal degeneration and progressive supranuclear palsy‐‐biochemical marker, Rinsho Shinkeigaku, 42, 1162
10.1016/j.jns.2007.03.016
10.1016/0304-3940(94)90746-3
10.1016/S0304-3940(99)00515-7
10.1016/j.nbd.2003.10.003
Mollenhauer B, 2007, A platform for the quantification of alpha‐synuclein in cerebrospinal fluid: evidence for a potential biomarker for synucleinopathies, Neurodegenerative Diseases, 4, 1
10.1016/0304-3940(89)90361-3
10.1016/S1474-4422(06)70355-6
10.1016/S0022-1759(00)00238-6
10.1016/j.parkreldis.2008.05.001
10.1111/j.1600-0404.2007.00985.x
10.1007/s00702-006-0511-9
Mollenhauer B, 2006, Proteome analysis of cerebrospinal fluid by mass spectrometry: A platform for marker development in synucleinopathies, Movement Disorders, 21, P780
10.1016/j.biopsych.2003.10.014
10.1097/01.wad.0000194014.43575.fd
10.1016/S0304-3940(01)01754-2
Huang RP, 2004, Cytokine protein arrays, Methods Mol Biol, 264, 215
